Status:
COMPLETED
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
Lead Sponsor:
AstraZeneca
Conditions:
Hay Fever
Perennial Allergic Rhinitis
Eligibility:
All Genders
2-5 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.
Eligibility Criteria
Inclusion
- Main
- General good health, other than perennial allergic rhinitis
- History and diagnosis of perennial allergic rhinitis by skin prick test
- History of perennial allergic rhinitis for a minimum of 90 days immediately before the screening visit
- Main
Exclusion
- Participation in any investigational drug trial within the 30 days before the screening visit
- Use of any disallowed concomitant medications within the prescribed withdrawal periods before the screening visit
- A known hypersensitivity to any corticosteroid
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00261287
Start Date
November 1 2005
End Date
June 1 2006
Last Update
November 30 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Altana Pharma/Nycomed
Long Beach, California, United States, 90806
2
Altana Pharma/Nycomed
Normal, Illinois, United States, 61761
3
Altana Pharma/Nycomed
San Antonio, Texas, United States, 78229